Healthcare Spending Accounts for 11.1% of GDP in Switzerland

DUBLIN, IRELAND, (NAMC) - Research and Markets has announced the addition of the Espicom Business Intelligence Ltd report: The Pharmaceutical Market: Switzerland to their offering.

Our in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

Topics Covered 1. Executive Summary  2. Pharmaceutical Market  3. Key National Data Projections  4. Geography  5. Political Overview  6. Economic Overview  7. Population  8. Demographic Indicators  9. Mortality  10. Morbidity  11. Organisation & Administration  12. Health Expenditure  13. Hospital Services  14. Ambulatory Care  15. Medical Personnel  16. Regulatory Environment  17. Distribution Channels  18. Pharmaceutical Imports  19. Domestic Production & Exports  20. Directory

Summary

Switzerland represents a very wealthy and mature pharmaceutical and healthcare market. Healthcare spending accounts for 11.1% of GDP, with per capita spending the second highest in the world after the USA. Swiss per capita spending on pharmaceuticals is estimated at US$630 in 2004, with the market itself worth US$4.7 billion at consumer prices.

Market development in recent years has been characterised by strong growth in the generics sector, with sales rising by almost 50% in 2003. While branded drugs still dominate the market, cost pressures will further increase generic usage. OTC market development is expected to slow, while growth of the reimbursable drug market is expected remain strong, due to rising private costs and patients paying greater contributions in general.

For more information visit http://www.researchandmarkets.com/reports/c48779